A biotech firm launched clinical trials in the Netherlands to test whether its cannabis chewing gum could help treat irritable bowel syndrome. And now, it is becoming an industry game changer.
IN 2017, a group of Researchers tested 40 adult patients and CanChew Plus chewing gum. CanChew contains 50 mg of hemp-derived cannabidiol per serving and is a cannabis chewing gum. Subjects were able to take up to six servings per day under the study. This helped to provide general relief of irritable bowel syndrome (IBS) symptoms. In addition, most patients often suffer from stomach cramps, bloating, and lower abdominal pain. Not to mention a “change in stool frequency.”
The mint-flavored chewing gum was developed by Axim Biotechnologies, which has offices in New York and the Netherlands.
“IBS is the most common gastrointestinal disorder and affects up to 15 percent of the worldwide population,” Axim CEO Dr. George E. Anastassov said in a statement. “And It has no sustainable cure.”
The forthcoming IBS trials were developed by Axim and clinical investigators at the Wageningen University, a leading Dutch research institution.
“IBS is a very common and often painful disorder which is still difficult to manage,” Renger Witkamp, a nutrition and pharmacology professor at the school. “People often experience sudden flare-ups and for many, it has a negative impact on their quality of life. CBD has shown to have promising effects. However, there has been a clear need for practical and effective formulations.”
While CBD is currently available in various forms, Witkamp claims that “providing it via a chewing gum results in sustained release of the compound and better bioavailability.”
Axim also makes CanChew, a controlled-release CBD chewing gum. In addition, the combination CBD/THC gum called MedChew Rx is currently undergoing clinical trials for the treatment of multiple sclerosis-related pain and spasticity. Standard CanChew gum is already available in all 50 US states, the company says, as it contains only hemp-based CBD.
Cannabis Chewing Gum could be a success
If the IBS trial is successful, Axim CEO Anastassov says, “we will be ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease.”
In a legal disclosure, the company says it “does not sell or distribute any products that are in violation of the United States Controlled Substances Act”—although the DEA might disagree.
After a year of the product being on the shelf, the product is growing and selling. This year there are hopes for expansion and pushing chewing gum into the market.
Furthermore, Global Cannabis Chewing Gum market studies record 2017 to 2022 affords an in-intensity assessment of the Cannabis Chewing Gum. This including enabling technologies, key trends, market drivers, challenges, standardization and regulatory landscape. In addition, deployment models, operator case research, possibilities, value chain, ecosystem player profiles, and strategies. The Report also provides forecasts for Cannabis Chewing Gum investments from 2017 till 2022.